Loading
Evolent Health, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 19 Nov 2025.
Evolent Health, Inc.: what insiders have been doing
Evolent Health, Inc. belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). Over the twelve months to 18 October 2026, 25 filings were filed, from 15 insiders.
On the market, 1 insider bought (1 purchase totalling €33k) while 1 insider sold (1 sale totalling €282k). Netting one side against the other leaves €249k of net selling. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. The buyers include 1 senior executive. McCarthy Daniel Joseph filed the largest sale, €282k, on 28 August 2026, which represents 0.078% of the company's market value.
The most recent open-market purchase was published on 19 November 2025, 333 days ago. Typically, a trade is published a median of 4 days after it takes place. For comparison, the SEC allows two business days to file a Form 4.
With 25 filings in twelve months, the company is more active than the median of 19 filings across the 5,816 companies we follow on the same exchange. Looking back to 2021, when coverage begins, insiders filed 10 purchases and 19 sales. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists revenue at 1.88 bn USD and net income at -534.5 m USD.
For comparison within the same sector, see the insider buying recorded at Cooper Companies, Inc. and Anixa Biosciences Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
188
Thresholds
n/a
Buy Volume
€1M
10 ops. · all time
Sell Volume
€5M
19 ops. · all time
Who traded when
BuySaleBrendan B. Springstubb2 buys
Daniel Joseph McCarthy1 buy1 sale
Craig A. Barbarosh1 buy
Holder Diane1 buy
Kim Keck1 buy
Peter J. Grua1 buy
+3 other insiders
Since the insiders bought
- -24.7%Entry US$3.69 · Close at T+90 US$2.78
- -67.8%Entry US$9.39 · Close at T+365 US$3.02
- -67.8%Entry US$9.39 · Close at T+365 US$3.02
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Evolent Health, Inc. Buy (bullish), based on 12 analysts. Average price target: US$5.75.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 22,538 of 24,148 companies
18.3
score / 100
Value23
Quality13
FCF yld0.9%
Earn yld-112%
EV/EBITDA·
ROE-67%
Gross mgn21%
Net mgn-31%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$4.60
Analyst consensus
12 analystsBuy
US$3.00Target US$5.75(+25%)US$8.00
Income statement
RevenueUS$1.9B
Gross profitUS$399.9M21% margin
EBITDA-US$361.3M-19% margin
Net income-US$579.4M-24.1% margin
Valuation
PER (forward)11.4x
P/Book1.4x
Beta1.02
Balance sheet & cash
Market capUS$520.1M
Total debtUS$989.7M
Free Cash FlowUS$4.8M
Debt / Equity253%
Profitability & ownership
ROE-67.0%
ROA-0.8%
% insiders3.1%
% institutions101.4%
Last declaration on 28 August 2026
Declarations188 total
65,892 shares@ US$5.000.078% mcap35.7% of flowClass A Common StockSEC:0001628908-26-000088:0
65,892 shares@ US$4.96990.078% mcap100.0% of flowCommonSEC144:0001628280-26-059130
446,102 shares0Class A Common StockSEC:0001628908-26-000070:0
10,297 shares@ US$5.740.014% mcap2.0% of flowClass A Common StockSEC:0001628908-26-000070:1
302,585 shares0Class A Common StockSEC:0001628908-26-000068:0
28,790 shares0Class A Common StockSEC:0001628908-26-000066:0
43,055 shares0Class A Common StockSEC:0001642833-26-000004:0
4,582 shares@ US$5.740.0064% mcap2.9% of flowClass A Common StockSEC:0001628908-26-000068:1
2,650 shares@ US$5.740.0037% mcap1.8% of flowClass A Common StockSEC:0001642833-26-000004:1
41,096 shares0Class A Common StockSEC:0001628908-26-000057:0
41,096 shares0Class A Common StockSEC:0001628908-26-000039:0
41,096 shares0Class A Common StockSEC:0001628908-26-000041:0
41,096 shares0Class A Common StockSEC:0001628908-26-000043:0
41,096 shares0Class A Common StockSEC:0001628908-26-000049:0
41,096 shares0Class A Common StockSEC:0001628908-26-000051:0
41,096 shares0Class A Common StockSEC:0001628908-26-000053:0
41,096 shares0Class A Common StockSEC:0001628908-26-000055:0
4,406 shares@ US$3.251.6% of flowClass A Common StockSEC:0001642833-26-000002:0
9,537 shares@ US$3.251.0% of flowClass A Common StockSEC:0001628908-26-000023:0
2,577 shares@ US$3.253.7% of flowClass A Common StockSEC:0001628908-26-000019:0
7,811 shares@ US$3.252.7% of flowClass A Common StockSEC:0001628908-26-000021:0
23,137 shares0Class A Common StockSEC:0001628908-26-000006:0
587,500 shares0Class A Common StockSEC:0001628908-26-000004:0
10,000 shares@ US$3.819920.4% of flowClass A Common StockSEC:0001628908-25-000138:0
Canonical exit: 16 Feb 2026 (T+90)
25 of 188 declarations
About Evolent Health, Inc.
Evolent Health, Inc. (NYSE: EVH) is a United States-listed healthcare company headquartered in Arlington, Virginia. Founded in the early 2010s by healthcare executives including Seth Blackley, the company built its platform around improving clinical outcomes and lowering the cost and administrative complexity of care for patients with complex conditions. From its origins as a value-based care platform, Evolent has evolved through a mix of organic growth and acquisitions into a more focused specialty care management business serving national payers and provider organizations across the United States. ([evolent.com](https://www.evolent.com/about-us))
Evolent’s core positioning is in specialty condition management and health care simplification. Its solution set spans performance-oriented care management, specialty technology and services, and administrative services. In practice, that means the company helps health plans and providers manage high-cost, high-variability areas such as oncology, cardiology, musculoskeletal care, surgical management and advanced imaging. Its model combines clinical expertise, data-driven workflows, automation and payer-provider collaboration to improve outcomes while reducing avoidable utilization and administrative burden. ([evolent.com](https://www.evolent.com/about-us))
Read moreShow less
From a competitive standpoint, Evolent is not trying to be a broad diversified health insurer or a generic services vendor. Instead, it competes as a specialist with deep clinical capabilities and a focused product stack aimed at complex conditions. That specialization is important in a market where rising medical costs and pressure to improve quality are pushing payers to seek external expertise. Management has repeatedly highlighted a strong selling environment, low market penetration in its addressable categories, and the ability to expand existing relationships by geography, line of business or service scope. ([ir.evolent.com](https://ir.evolent.com/2025-05-08-Evolent-Announces-First-Quarter-2025-Results))
The company’s growth history has been shaped by acquisitions designed to broaden its specialty footprint. Notable transactions include New Century Health, IPG and Vital Decisions, which expanded Evolent’s capabilities in specialty care, surgical management and advance care planning. More recently, Evolent announced the divestiture of Evolent Care Partners, its value-based primary care business, to sharpen its focus on specialty condition management and accelerate deleveraging. That move signals a more disciplined portfolio strategy and a clearer emphasis on cash generation and balance-sheet improvement. ([ir.evolent.com](https://ir.evolent.com/2018-10-02-Evolent-Health-Completes-Acquisition-of-New-Century-Health?utm_source=openai))
Geographically, Evolent operates primarily in the United States and serves a national client base rather than being concentrated in a single region. Recent disclosures show deployments across multiple lines of business, including Medicare Advantage, Medicaid and commercial plans, with new wins and expansions in several U.S. markets. At the start of 2025, the company reported five new revenue agreements and reiterated full-year guidance, while also emphasizing its growing pipeline, AI-enabled automation initiatives and continued focus on profitability and debt paydown. For investors, EVH is a U.S. healthcare services name with a specialized growth profile, meaningful execution leverage and exposure to both demand tailwinds and reimbursement/regulatory complexity. ([ir.evolent.com](https://ir.evolent.com/2025-05-08-Evolent-Announces-First-Quarter-2025-Results))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
